Related Experiment Videos
Involvement of IGF-II in human cancer
1Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Abstract:
IGF-II is a regulatory peptide which appears to be involved significantly in the progression of many tumors, while minimally involved in post-fetal non-tumor tissue. Interruption of IGF-II pathways therefore offers the possibility of tumor control with a high therapeutic index. Investigators should continue to evaluate tumors for the involvement of IGF-II as well as investigate clinically relevant means of disrupting those pathways.
Insights
Insulin-like Growth Factor II (IGF-II) significantly drives tumor progression but minimally affects normal tissues. Targeting IGF-II pathways offers a promising strategy for cancer treatment with a favorable safety profile.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Insulin-like Growth Factor II (IGF-II) is a key regulatory peptide.
- IGF-II plays a significant role in the progression of various tumors.
- Its involvement in non-tumorigenic, post-fetal tissues is minimal.
Purpose of the Study:
- To highlight the critical role of IGF-II in tumor development.
- To propose IGF-II pathway interruption as a therapeutic strategy for cancer.
- To emphasize the potential for a high therapeutic index in targeting IGF-II.
Main Methods:
- Review of existing literature on IGF-II's role in tumorigenesis.
- Analysis of IGF-II's differential involvement in tumor versus normal tissues.
- Evaluation of potential therapeutic strategies targeting IGF-II pathways.
Main Results:
- IGF-II is significantly implicated in the progression of numerous cancers.
- IGF-II has limited involvement in healthy, adult tissues.
- Targeting IGF-II pathways presents a viable approach for tumor control.
Conclusions:
- The selective involvement of IGF-II in tumors suggests it as a prime therapeutic target.
- Interruption of IGF-II pathways can lead to effective tumor control.
- Further investigation into clinically relevant methods for disrupting IGF-II pathways is warranted.